See more : Man Industries (India) Limited (MANINDS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Silo Pharma, Inc. (SILO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silo Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ningbo Ronbay New Energy Technology Co., Ltd. (688005.SS) Income Statement Analysis – Financial Results
- Vodafone Group Public Limited Company (VODPF) Income Statement Analysis – Financial Results
- Rede Energia Participações S.A. (REDE3.SA) Income Statement Analysis – Financial Results
- Marker Therapeutics, Inc. (MRKR) Income Statement Analysis – Financial Results
- LS Berkshire Hathaway (BRK-B) Tracker ETP Securities (BERK.L) Income Statement Analysis – Financial Results
Silo Pharma, Inc. (SILO)
About Silo Pharma, Inc.
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.10K | 72.10K | 71.26K | 40.92K | 40.57K | 0.00 | 847.41K | -669.48K | -145.19K | -107.11K | 105.52K | 0.00 | 0.00 |
| Cost of Revenue | 5.84K | 5.84K | 5.00K | 176.13K | 27.39K | 17.55K | 0.00 | 0.00 | 0.00 | -127.68K | 104.90K | 0.00 | 0.00 |
| Gross Profit | 66.26K | 66.26K | 66.26K | -135.20K | 13.18K | -17.55K | 847.41K | -669.48K | -145.19K | 20.57K | 625.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 91.90% | 91.90% | 92.98% | -330.38% | 32.49% | 0.00% | 100.00% | 100.00% | 100.00% | -19.20% | 0.59% | 0.00% | 0.00% |
| Research & Development | 845.09K | 1.29M | 693.91K | 88.80K | 63.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.08M | 2.43M | 2.27M | 2.18M | 864.18K | 459.83K | 313.37K | 300.99K | 167.70K | 269.44K | 72.61K | 39.45K | 49.80K |
| Selling & Marketing | 0.00 | -1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.08M | 2.43M | 2.27M | 2.18M | 864.18K | 459.83K | 313.37K | 300.99K | 167.70K | 269.44K | 72.61K | 39.45K | 49.80K |
| Other Expenses | 0.00 | 2.17M | 1.95M | 3.00K | 765.72K | 314.61K | 177.50K | 142.50K | 96.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.92M | 3.71M | 2.96M | 2.27M | 927.65K | 459.83K | 490.87K | 443.49K | 264.31K | 269.44K | 72.61K | 39.45K | 49.80K |
| Cost & Expenses | 3.93M | 3.72M | 2.96M | 2.45M | 955.03K | 459.83K | 427.96K | 443.49K | 264.31K | 269.44K | 72.61K | 39.45K | 49.80K |
| Interest Income | 398.53K | 72.64K | 1.21K | 11.54K | 12.20K | 4.22K | 20.48K | 49.84K | 40.34K | 20.57K | 625.00 | 0.00 | 0.00 |
| Interest Expense | 4.87K | 2.20K | 3.04K | 269.27K | 62.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 229.38K | 72.64K | -147.29K | 179.92K | 28.14K | 17.55K | -701.10K | 719.32K | 192.33K | 127.68K | -104.90K | 0.00 | 0.00 |
| EBITDA | -3.63M | -3.91M | 4.19M | -2.39M | -930.40K | -951.91K | 0.00 | 0.00 | -217.17K | -248.87K | -71.99K | -39.45K | -49.80K |
| EBITDA Ratio | -5,029.28% | -4,958.28% | -4,057.63% | -5,847.68% | -2,224.03% | 0.00% | -138.24% | -48.64% | 17.11% | 113.14% | -167.63% | 0.00% | 0.00% |
| Operating Income | -3.86M | -3.65M | -2.74M | -2.57M | -930.40K | -594.24K | -470.39K | -393.66K | -217.17K | -248.87K | -71.99K | -39.45K | -49.80K |
| Operating Income Ratio | -5,347.41% | -5,059.02% | -3,850.95% | -6,287.34% | -2,293.38% | 0.00% | -55.51% | 58.80% | 149.58% | 232.34% | -68.22% | 0.00% | 0.00% |
| Total Other Income/Expenses | 224.51K | -279.73K | 6.93M | -464.55K | -82.89K | -375.22K | 826.92K | -719.32K | -192.33K | 0.00 | 104.90K | 0.00 | 0.00 |
| Income Before Tax | -3.63M | -3.91M | 4.18M | -3.04M | -1.01M | -969.46K | 356.54K | -1.11M | -409.50K | -376.55K | 32.91K | -39.45K | -49.80K |
| Income Before Tax Ratio | -5,036.04% | -5,419.25% | 5,868.30% | -7,422.52% | -2,497.71% | 0.00% | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.16K | 24.88K | 92.35K | 34.79K | -513.85K | -62.91K | 696.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -3.70M | -3.91M | 3.90M | -3.13M | -1.05M | -969.46K | 356.54K | -1.11M | -409.50K | -376.55K | 32.91K | -39.45K | -49.80K |
| Net Income Ratio | -5,132.57% | -5,420.86% | 5,477.86% | -7,648.18% | -2,583.47% | 0.00% | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | 0.00% | 0.00% |
| EPS | -1.20 | -1.71 | 2.06 | -2.37 | -1.24 | -0.99 | 0.50 | -1.11 | -0.40 | -0.39 | 0.05 | -0.06 | -0.08 |
| EPS Diluted | -1.20 | -1.71 | 2.03 | -2.37 | -1.24 | -0.99 | 0.50 | -1.11 | -0.40 | -0.39 | 0.05 | -0.06 | -0.08 |
| Weighted Avg Shares Out | 3.08M | 2.28M | 1.90M | 1.32M | 842.30K | 982.03K | 1.00M | 1.00M | 1.01M | 958.30K | 648.74K | 612.62K | 612.62K |
| Weighted Avg Shares Out (Dil) | 3.08M | 2.28M | 1.92M | 1.32M | 842.30K | 982.03K | 1.04M | 1.00M | 1.01M | 958.30K | 648.74K | 612.62K | 612.62K |
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
MedSpray's patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer's disease, and anorexia ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental...
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial
Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
Human tissue study assessed SPU-21's efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive...
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
Investigational New Drug (IND) submission to FDA on target for Q1 2024
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
Clarivate will monitor, manage, and maintain Company's expanding IP portfolio ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today...
Silo Pharma shares take off as anxiety and PTSD therapeutic candidate achieves milestone
Silo Pharma shares rose on Tuesday after the development stage biopharmaceutical company announced it has advanced the formulation development of its therapeutic candidate SPC-15, achieving a liquid nasal formulation. This formulation of SPC-15, a targeted prophylactic treatment using ketamine compositions,...
Silo Pharma to Present at Psychedelic Drug Development Conference
ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D., Vice President of R&D, will...
7 Top Penny Stocks To Watch With Big News This Week
Penny Stocks With News Light Up The Scanners This Week This week
Source: https://incomestatements.info
Category: Stock Reports